Optimer Pharmaceuticals LLC
(NASDAQ : OPTR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -2.78%151.880.7%$1185.40m
PFEPfizer Inc. -1.35%33.930.9%$1169.30m
MRKMerck & Co., Inc. -1.88%71.930.7%$848.30m
BMYBristol-Myers Squibb Co. -2.91%58.991.0%$788.61m
ABBVAbbVie, Inc. -1.46%105.151.9%$735.20m
LLYEli Lilly & Co. -1.34%199.291.1%$638.61m
AZNAstraZeneca Plc -1.13%46.631.2%$491.58m
GSKGlaxoSmithKline Plc -0.76%33.980.2%$281.50m
NVSNovartis AG -1.67%82.780.2%$164.35m
SNYSanofi -0.01%45.460.2%$156.14m
VTRSViatris, Inc. -3.47%13.400.0%$146.57m
VERUVeru, Inc. -11.41%11.650.0%$96.90m
NVONovo Nordisk A/S -3.74%68.790.1%$83.95m
KALVKalVista Pharmaceuticals, Inc. -3.48%31.070.4%$80.83m
RPRXRoyalty Pharma Plc -4.25%41.720.2%$79.35m

Company Profile

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.